Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection
- 1 November 2018
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The Pediatric Infectious Disease Journal
- Vol. 37 (11), 1130-1136
- https://doi.org/10.1097/INF.0000000000002170
Abstract
Background: Drug-resistant Gram-negative bacteria are a growing threat to children; thus new antibiotics are needed to treat infections caused by these pathogens. Ceftolozane/tazobactam is active against many Gram-negative pathogens and is approved for treatment of complicated intra-abdominal and urinary tract infections in adults, but has not been evaluated in children. Methods: This phase 1, noncomparative, open-label, multicenter study characterized the pharmacokinetics (by noncompartmental analysis), safety, and tolerability of single intravenous doses of ceftolozane/tazobactam in pediatric patients (birth [7 days postnatal] to < 18 years of age) with proven/suspected Gram-negative infection or receiving perioperative prophylaxis (clinicaltrials.gov NCT02266706). Patients were enrolled into 1 of 6 age groups to receive a single, age-based ceftolozane/tazobactam dose, with timed blood sample collection for determining plasma concentrations of ceftolozane and tazobactam. Safety and tolerability were also evaluated. Results: Thirty-seven patients received study drug; 34 were included in the pharmacokinetic population. Ceftolozane and tazobactam pharmacokinetic parameters were generally comparable for patients 3 months to < 18 years of age. Patients from birth (7 days postnatal) to < 3 months of age had lower clearance than older children, likely due to the immature renal function of these young infants. No deaths, study drug-related serious adverse events, or clinically significant laboratory abnormalities were observed after administration of ceftolozane/tazobactam. Conclusions: The doses evaluated in this study yielded ceftolozane/tazobactam exposure levels generally comparable with those in adults. Single doses of ceftolozane/tazobactam were well-tolerated, and no safety concerns were identified. These data informed pharmacokinetic/pharmacodynamic models to derive pediatric dose recommendations for phase 2 ceftolozane/tazobactam clinical trials.Keywords
This publication has 25 references indexed in Scilit:
- Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-TazobactamAntimicrobial Agents and Chemotherapy, 2014
- Extended-Spectrum β-Lactamase–Producing and Third-Generation Cephalosporin-Resistant Enterobacteriaceae in Children: Trends in the United States, 1999–2011Journal of the Pediatric Infectious Diseases Society, 2014
- In Vivo Activities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic MiceAntimicrobial Agents and Chemotherapy, 2013
- Subtherapeutic Initial β-Lactam Concentrations in Select Critically Ill PatientsSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending DosesAntimicrobial Agents and Chemotherapy, 2012
- Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and AdultsPharmaceutics, 2011
- New Equations to Estimate GFR in Children with CKDJournal of the American Society of Nephrology, 2009
- Human renal function maturation: a quantitative description using weight and postmenstrual agePediatric Nephrology, 2009
- Inhibition of the renal excretion of tazobactam by piperacillinJournal of Antimicrobial Chemotherapy, 1994
- Antibiotic Pharmacokinetics in Cystic FibrosisClinical Pharmacokinetics, 1987